<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00303901</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000462091</org_study_id>
    <secondary_id>P30CA022453</secondary_id>
    <secondary_id>WSU-C-2975</secondary_id>
    <secondary_id>WSU-0509002942</secondary_id>
    <nct_id>NCT00303901</nct_id>
  </id_info>
  <brief_title>Cryotherapy in Treating Patients With Primary Lung Cancer or Lung Metastases That Cannot Be Removed By Surgery</brief_title>
  <official_title>Percutaneous Thoracic Cryotherapy (PTC) for Inoperable Primary Lung Cancer and Metastatic Management</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Barbara Ann Karmanos Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Barbara Ann Karmanos Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Cryotherapy kills tumor cells by freezing them. This may be an effective treatment
      for primary lung cancer or lung metastases that cannot be removed by surgery.

      PURPOSE: This clinical trial is studying how well cryotherapy works in treating patients with
      primary lung cancer or lung metastases that cannot be removed by surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Estimate the local and distant failure rates after percutaneous thoracic cryotherapy
           (PTC) in patients with unresectable primary lung cancer or lung metastases.

        -  Estimate rates of PTC complications and adverse reactions.

        -  Determine the correlations between procedural parameters and follow-up imaging
           parameters, with the latter being used as surrogates of local and/or distant treatment
           failure.

      OUTLINE: Patients undergo CT-guided percutaneous thoracic cryotherapy over 2 hours under
      local or general anesthesia. Grouped cryoprobes are inserted into the tumor, utilizing a
      freeze-thaw-freeze cycle, creating cytotoxic temperatures (less than -20°C to -40°C) that
      encompass the entire anticipated tumor volume.

      Patients undergo positron emission tomography at baseline and after cryotherapy to assess
      tumor standard uptake variable.

      After completion of study treatment, patients are followed at 1, 3, 6 and 12 months.

      PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2005</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Local Failure Rates by CT Scan</measure>
    <time_frame>at 3, 6, and 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distant Failure Rate</measure>
    <time_frame>at 3, 6, and 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of Complications and Adverse Reactions by Occurrences of Toxicities</measure>
    <time_frame>at 3, 6, and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlate Procedural Parameters and Follow-up Imaging Parameters</measure>
    <time_frame>at 3, 6, and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Point and Exact Confidence Interval Estimates of Patients Who Undergo Multiple Cryotherapy Procedures</measure>
    <time_frame>12 months after the last patient was enrolled</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Lung Cancer</condition>
  <condition>Metastatic Cancer</condition>
  <arm_group>
    <arm_group_label>cryosurgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>cryoprobe is placed in the proper position using CT imaging guidance, and as internal tissue is being frozen, the physician avoids damaging healthy tissue by viewing the movement of the probe on CT images transmitted to a monitor similar to a television screen. Living tissue, healthy or diseased, cannot withstand extremely cold conditions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>cryosurgery</intervention_name>
    <arm_group_label>cryosurgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>positron emission tomography</intervention_name>
    <arm_group_label>cryosurgery</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically or cytologically confirmed malignant pulmonary neoplasm

          -  New lung lesion(s) with definitive clinical and imaging features of primary or
             metastatic disease allowed

               -  Imaging findings compatible with localized treatment failure after prior
                  cryotherapy allowed

          -  Malignant pleural effusion allowed provided it is associated with a distinct
             measurable pulmonary mass amenable to cryotherapy

          -  Metastatic disease must meet all of the following criteria:

               -  Primary tumors have been resected or have been deemed controlled by other
                  therapies

               -  No other widespread metastases evident (e.g., multiple hepatic or brain
                  metastases)

          -  Each pulmonary mass must be amenable to CT-guided percutaneous cryotherapy approach

          -  No more than 5 targeted masses for study therapy

               -  Target mass defined as pulmonary, hilar, mediastinal, and/or chest wall mass &gt; 1
                  cm, but &lt; 10 cm in average diameter

          -  Unresectable disease by surgical consultation OR patient refused surgical options

          -  Nonenhanced and enhanced CT scan required within the past 6 weeks done at 4-5 mm
             increments with available soft tissue and mediastinal windows to assess size and
             extent of all thoracic tumors

               -  PET scan required within the past 6 months noting the correlation with the above
                  CT locations, if not already obtained by a combined PET/CT scanner

        PATIENT CHARACTERISTICS:

          -  Karnofsky performance status (PS) &gt; 60-100% OR WHO/ECOG/Zubrod PS 0-2

          -  FEV_1 &gt; 30% of predicted

          -  DLCO &gt; 40% of predicted

          -  Platelet count ≥ 70,000/mm^3

          -  INR &lt; 1.5

          -  No uncontrolled coagulopathy or bleeding diathesis

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  No serious medical illness, including any of the following:

               -  Uncontrolled congestive heart failure

               -  Uncontrolled angina

               -  Myocardial infarction

               -  Cerebrovascular event within 6 months prior to study entry

          -  No medical contraindication or potential problem that would preclude study compliance

        PRIOR CONCURRENT THERAPY:

          -  At least 7 days since prior aspirin and aspirin-like medications

          -  At least 3 days since prior warfarin, clopidogrel bisulfate, or similar compounds

          -  No concurrent drugs causing bleeding tendencies (e.g., aspirin, warfarin, or
             clopidogrel bisulfate)

          -  No concurrent participation in other experimental studies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter J. Littrup, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Barbara Ann Karmanos Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Barbara Ann Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201-1379</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 15, 2006</study_first_submitted>
  <study_first_submitted_qc>March 15, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2006</study_first_posted>
  <results_first_submitted>February 9, 2015</results_first_submitted>
  <results_first_submitted_qc>February 9, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 23, 2015</results_first_posted>
  <last_update_submitted>February 9, 2015</last_update_submitted>
  <last_update_submitted_qc>February 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Barbara Ann Karmanos Cancer Institute</investigator_affiliation>
    <investigator_full_name>Peter Littrup</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>lung metastases</keyword>
  <keyword>recurrent non-small cell lung cancer</keyword>
  <keyword>recurrent small cell lung cancer</keyword>
  <keyword>stage I non-small cell lung cancer</keyword>
  <keyword>stage II non-small cell lung cancer</keyword>
  <keyword>stage IIIA non-small cell lung cancer</keyword>
  <keyword>stage IIIB non-small cell lung cancer</keyword>
  <keyword>stage IV non-small cell lung cancer</keyword>
  <keyword>extensive stage small cell lung cancer</keyword>
  <keyword>limited stage small cell lung cancer</keyword>
  <keyword>pulmonary carcinoid tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Cryosurgery</title>
          <description>cryoprobe is placed in the proper position using CT imaging guidance, and as internal tissue is being frozen, the physician avoids damaging healthy tissue by viewing the movement of the probe on CT images transmitted to a monitor similar to a television screen. Living tissue, healthy or diseased, cannot withstand extremely cold conditions.
cryosurgery
positron emission tomography</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cryosurgery</title>
          <description>cryoprobe is placed in the proper position using CT imaging guidance, and as internal tissue is being frozen, the physician avoids damaging healthy tissue by viewing the movement of the probe on CT images transmitted to a monitor similar to a television screen. Living tissue, healthy or diseased, cannot withstand extremely cold conditions.
cryosurgery
positron emission tomography</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Local Failure Rates by CT Scan</title>
        <time_frame>at 3, 6, and 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cryosurgery</title>
            <description>cryoprobe is placed in the proper position using CT imaging guidance, and as internal tissue is being frozen, the physician avoids damaging healthy tissue by viewing the movement of the probe on CT images transmitted to a monitor similar to a television screen. Living tissue, healthy or diseased, cannot withstand extremely cold conditions.
cryosurgery
positron emission tomography</description>
          </group>
        </group_list>
        <measure>
          <title>Local Failure Rates by CT Scan</title>
          <units>% of participants with local recurrence</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15" lower_limit="7" upper_limit="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Complications and Adverse Reactions by Occurrences of Toxicities</title>
        <time_frame>at 3, 6, and 12 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Correlate Procedural Parameters and Follow-up Imaging Parameters</title>
        <time_frame>at 3, 6, and 12 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Point and Exact Confidence Interval Estimates of Patients Who Undergo Multiple Cryotherapy Procedures</title>
        <time_frame>12 months after the last patient was enrolled</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Distant Failure Rate</title>
        <time_frame>at 3, 6, and 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cryosurgery</title>
            <description>cryoprobe is placed in the proper position using CT imaging guidance, and as internal tissue is being frozen, the physician avoids damaging healthy tissue by viewing the movement of the probe on CT images transmitted to a monitor similar to a television screen. Living tissue, healthy or diseased, cannot withstand extremely cold conditions.
cryosurgery
positron emission tomography</description>
          </group>
        </group_list>
        <measure>
          <title>Distant Failure Rate</title>
          <units>% of participants with distant failure</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.5" lower_limit="37" upper_limit="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Cryosurgery</title>
          <description>cryoprobe is placed in the proper position using CT imaging guidance, and as internal tissue is being frozen, the physician avoids damaging healthy tissue by viewing the movement of the probe on CT images transmitted to a monitor similar to a television screen. Living tissue, healthy or diseased, cannot withstand extremely cold conditions.
cryosurgery
positron emission tomography</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Severe atrial flutter</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Deconditioning</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection with normal ANC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Progressive weakness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic arteriovenous fistua</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis (DVT)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest wall pain</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Hemoptysis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Pulmonary Hemorrhage</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>There were no study limitations.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Peter Littrup, M.D.</name_or_title>
      <organization>Barbara Ann Karmanos Cancer Institute</organization>
      <phone>313-576-8758</phone>
      <email>littrupp@karmanos.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

